Scalper1 News
Generic-drug giant Mylan (MYL) agreed to develop six biosimilar drugs with biotech Momenta Pharmaceuticals (MNTA) Friday while also announcing the retirement of its CFO. Momenta got an upgrade as a result. Mylan agreed to pay $45 million upfront plus up to $200 million in milestone payments should the candidates be successful, in exchange for commercialization rights. Momenta has the option to “co-commercialize in a supporting commercial role, any Scalper1 News
Scalper1 News